Cell Therapy & Immuno-Engineering Program, Center for ImmunoTherapy and Precision Immuno-Oncology, Lerner College of Medicine, Cleveland Clinic, Cleveland, OH.
Cell Therapy & Immuno-Engineering Program, Center for ImmunoTherapy and Precision Immuno-Oncology, Lerner College of Medicine, Cleveland Clinic, Cleveland, OH.
Semin Hematol. 2023 Jan;60(1):25-33. doi: 10.1053/j.seminhematol.2023.01.002. Epub 2023 Feb 8.
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape of blood cancers. These engineered receptors which endow T cells with antibody-like target cell recognition combined with the typical T cell target cell lysis abilities. Introduced into the clinic in the 2010s, CAR T-cells have shown efficacy in chronic B lymphocytic leukemia (CLL), but a majority of patients do not achieve sustained remission. Here we discuss the current treatment landscape in CLL using small molecules and allogeneic stem cell transplantation, the niche CAR T-cells filled in this context, and what we have learned from biomarker and mechanistic studies. Several product parameters and improvements are introduced as examples of how the bedside-to-bench is translated into improved CAR T-cells for CLL. We hope to convey to our readers the crucial role translational medicine plays in transforming the treatment outcomes for patients with CLL and how this line of research is an essential component of modern medicine.
嵌合抗原受体 (CAR) T 细胞疗法改变了血液癌症的治疗格局。这些经过工程改造的受体使 T 细胞具有类似抗体的靶细胞识别能力，并结合 T 细胞典型的靶细胞裂解能力。CAR T 细胞于 21 世纪 10 年代引入临床，在慢性 B 淋巴细胞白血病 (CLL) 中显示出疗效，但大多数患者无法获得持续缓解。在这里，我们讨论了使用小分子和同种异体干细胞移植的 CLL 当前治疗领域，CAR T 细胞在这方面的应用，以及我们从生物标志物和机制研究中了解到的内容。我们引入了几个产品参数和改进，作为将床边到病床的转化为改善 CLL 的 CAR T 细胞的示例。我们希望向读者传达转化医学在改变 CLL 患者治疗结果方面所起的关键作用，以及这条研究路线如何成为现代医学的重要组成部分。
